NASDAQ:BRKR - Bruker Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$34.20 +0.22 (+0.65 %)
(As of 08/19/2018 03:14 PM ET)
Previous Close$34.20
Today's Range$33.83 - $34.30
52-Week Range$27.43 - $36.53
Volume402,900 shs
Average Volume612,038 shs
Market Capitalization$5.30 billion
P/E Ratio28.26
Dividend Yield0.47%
Beta1.17
Bruker logoBruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, and defect-detection equipment for semiconductor process control, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments and spark optical emission spectroscopy systems. In addition, it offers superconducting and non-superconducting materials and devices. The company serves pharmaceutical, biotechnology and diagnostics, chemical, food and beverage, clinical, polymer, nanotechnology, semiconductor, and industrial companies; nonprofit laboratories; contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals, and government departments and agencies; and raw material manufacturers, and other businesses involved in materials analysis. It markets its products through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was founded in 1991 and is headquartered in Billerica, Massachusetts.

Receive BRKR News and Ratings via Email

Sign-up to receive the latest news and ratings for BRKR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
SymbolNASDAQ:BRKR
CUSIP11679410
Phone978-663-3660

Debt

Debt-to-Equity Ratio0.26
Current Ratio2.22
Quick Ratio1.27

Price-To-Earnings

Trailing P/E Ratio28.26
Forward P/E Ratio24.78
P/E Growth2.14

Sales & Book Value

Annual Sales$1.77 billion
Price / Sales3.03
Cash Flow$1.6626 per share
Price / Cash20.57
Book Value$4.72 per share
Price / Book7.25

Profitability

EPS (Most Recent Fiscal Year)$1.21
Net Income$78.60 million
Net Margins4.99%
Return on Equity27.03%
Return on Assets10.92%

Miscellaneous

Employees6,200
Outstanding Shares156,320,000
Market Cap$5.30 billion

Bruker (NASDAQ:BRKR) Frequently Asked Questions

What is Bruker's stock symbol?

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

How often does Bruker pay dividends? What is the dividend yield for Bruker?

Bruker declared a quarterly dividend on Monday, August 13th. Stockholders of record on Tuesday, September 4th will be paid a dividend of $0.04 per share on Friday, September 21st. This represents a $0.16 annualized dividend and a dividend yield of 0.47%. The ex-dividend date is Friday, August 31st. View Bruker's Dividend History.

How will Bruker's stock buyback program work?

Bruker declared that its Board of Directors has authorized a share repurchase plan on Sunday, June 4th 2017, which authorizes the company to buyback $225,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's management believes its stock is undervalued.

How were Bruker's earnings last quarter?

Bruker Co. (NASDAQ:BRKR) announced its quarterly earnings results on Thursday, August, 2nd. The medical research company reported $0.25 earnings per share for the quarter, meeting analysts' consensus estimates of $0.25. The medical research company earned $443.70 million during the quarter, compared to analysts' expectations of $436.10 million. Bruker had a net margin of 4.99% and a return on equity of 27.03%. Bruker's revenue for the quarter was up 6.9% on a year-over-year basis. During the same period last year, the business earned $0.23 earnings per share. View Bruker's Earnings History.

When is Bruker's next earnings date?

Bruker is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Bruker.

What guidance has Bruker issued on next quarter's earnings?

Bruker updated its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share guidance of $1.34-1.38 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.38. The company issued revenue guidance of approx $1.88 billion, compared to the consensus revenue estimate of $1.88 billion.

What price target have analysts set for BRKR?

9 Wall Street analysts have issued 1-year price targets for Bruker's shares. Their forecasts range from $24.00 to $42.00. On average, they expect Bruker's stock price to reach $33.1111 in the next year. This suggests that the stock has a possible downside of 3.2%. View Analyst Price Targets for Bruker.

What is the consensus analysts' recommendation for Bruker?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bruker in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bruker.

Who are some of Bruker's key competitors?

Who are Bruker's key executives?

Bruker's management team includes the folowing people:
  • Dr. Frank H. Laukien, Chairman, CEO & Pres (Age 58)
  • Dr. Mark R. Munch, Exec. VP and Pres of Bruker Nano Group & Bruker Nano Surfaces Division (Age 56)
  • Mr. Juergen Srega, Pres of Bruker CALID Group & Bruker Daltonics Division (Age 63)
  • Mr. Gerald N. Herman, CFO, VP & Corp. Controller (Age 60)
  • Stacey Desrochers, Treasurer & Director of Investor Relations

Has Bruker been receiving favorable news coverage?

Media headlines about BRKR stock have been trending somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bruker earned a news and rumor sentiment score of 0.11 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 46.87 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Bruker.

Who are Bruker's major shareholders?

Bruker's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (4.76%), BlackRock Inc. (3.43%), Acadian Asset Management LLC (3.02%), Millennium Management LLC (0.82%), Epoch Investment Partners Inc. (0.72%) and Dimensional Fund Advisors LP (0.62%). Company insiders that own Bruker stock include Frank H Laukien, Ingen Chris Van, Mark Munch and Richard Kniss. View Institutional Ownership Trends for Bruker.

Which institutional investors are selling Bruker stock?

BRKR stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Acadian Asset Management LLC, First Trust Advisors LP, Sensato Investors LLC, Janus Henderson Group PLC, First Quadrant L P CA, Eagle Asset Management Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Bruker.

Which institutional investors are buying Bruker stock?

BRKR stock was bought by a variety of institutional investors in the last quarter, including Epoch Investment Partners Inc., Citadel Advisors LLC, Fuller & Thaler Asset Management Inc., Los Angeles Capital Management & Equity Research Inc., Point72 Asset Management L.P., Millennium Management LLC, CWM LLC and MUFG Securities EMEA plc. View Insider Buying and Selling for Bruker.

How do I buy shares of Bruker?

Shares of BRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bruker's stock price today?

One share of BRKR stock can currently be purchased for approximately $34.20.

How big of a company is Bruker?

Bruker has a market capitalization of $5.30 billion and generates $1.77 billion in revenue each year. The medical research company earns $78.60 million in net income (profit) each year or $1.21 on an earnings per share basis. Bruker employs 6,200 workers across the globe.

How can I contact Bruker?

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company can be reached via phone at 978-663-3660 or via email at [email protected]


MarketBeat Community Rating for Bruker (NASDAQ BRKR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  495 (Vote Outperform)
Underperform Votes:  548 (Vote Underperform)
Total Votes:  1,043
MarketBeat's community ratings are surveys of what our community members think about Bruker and other stocks. Vote "Outperform" if you believe BRKR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BRKR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.